Blue Sail Medical Secures RMB 900 Million Investment for R&D and Capacity Expansion
Blue Sail Medical Co., Ltd (SHE: 002382) has announced that its wholly owned subsidiary, Blue...
3D Medicines Partners with Sino Cellbiomed to Advance Tumor Immunotherapy Development
3D Medicines (HKG: 1244), a China-based oncology specialist, has entered into a partnership with Sino...
Mindray to Acquire 21.12% Stake in APT Medical for RMB 6.652 Billion
Mindray (SHE: 300760), a leading China-based medtech firm, has announced plans to acquire a 21.12%...
Johnson & Johnson’s Rybrevant and Lazertinib Filings Accepted for Review by CDE
The Center for Drug Evaluation (CDE) has confirmed that Johnson & Johnson’s (J&J, NYSE: JNJ)...
EMA’s CHMP Endorses Bristol Myers Squibb’s CAR-T Therapy Abecma for Multiple Myeloma
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Dupixent by Sanofi and Regeneron Approved by FDA for Eosinophilic Esophagitis in Younger Pediatric Patients
The US Food and Drug Administration (FDA) has concluded a priority review and granted approval...
Shandong Boan Biotechnology Strikes Licensing Deal with Joincare for Long-Acting mAb BA2101
Shandong Boan Biotechnology Co., Ltd (HKG: 6955), based in China, has announced a licensing agreement...
Apeloa Pharmaceutical Halts Phase III Trial of Salfaprodil for Acute Ischemic Stroke
Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a China-based pharmaceutical company, has announced the termination of...
Laekna Therapeutics Reports Phase II Data for Afuresertib in Platinum-Resistant Ovarian Cancer
Laekna Therapeutics Shanghai Co., Ltd, a China-based pharmaceutical company, has announced topline data from the...
Zhaoke Ophthalmology Strikes Distribution Deal with South Korea’s Kwangdong Pharmaceutical for Brimochol PF
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a China-based pharmaceutical company, through its subsidiary Zhaoke Ophthalmology...
Yantai Dongcheng’s Radiopharmaceutical 68GaLNC1007 Gets FDA Nod for Diagnostic Use in Solid Tumors
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has announced that...
Joincare Pharmaceutical Partners with QYuns Therapeutics for Exclusive Rights to QX008N in China and Hong Kong
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced a...
Formosa Pharmaceuticals Strikes Licensing Deal with Cristália for Ocular Surgery Pain Treatment in Brazil
Taiwan-based Formosa Pharmaceuticals (TPE: 6838) has announced the signing of a licensing agreement with Brazil-based...
Lonza Announces Factory Closures in the US and China Amid Global Network Optimization
Swiss Contract Manufacturing Organization (CMO) Lonza has released its 2023 financial report, which includes plans...
China-Based Biotechs Respond to US House Bill Limiting Federal Funding for ‘Concerning’ Companies
A bipartisan bill introduced on January 26, 2024, by members of the US House Select...
Eisai’s Alzheimer’s Drug Leqembi Earns Marketing Approval in China
Eisai (TYO: 4523), a leading Japanese pharmaceutical company, has announced that it has received marketing...
Wuxi National Hi-Tech District Welcomes Synthetic Biology Industrial Park and East China’s First R&D Center
The Wuxi National Hi-Tech District (WND) has welcomed the opening of a new synthetic biology...
Kingmed Diagnostics and MegaRobo Technologies Join Forces to Pioneer Smart Medical Laboratories
Kingmed Diagnostics (SHA: 603882), a prominent independent medical laboratory headquartered in Guangdong, is poised to...
Henlius Biotech Ships First International Batch of HanSiZhuang for Cancer Treatment to Indonesia
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biotech company from China, has announced the...
Shanghai Fosun Pharmaceutical Receives NMPA Approval for Phase II Study of FCN-338 for Light Chain Amyloidosis
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...